Acute lung injury (ALI) and its more severe form acute respiratory distress syndrome (ARDS) are life-threatening conditions with high morbility and mortality, underscoring the urgent need for novel treatments. Leaves of the medicinal herb Microcos paniculata have been traditionally used for treating upper airway infections, by virtue of its content of flavonoids such as apigenin C-glycosides (ACGs). C-glycosides have been shown to exert strong anti-inflammatory properties, although their mechanism of action remains unknown. Herein, hypothesizing that ACGs from M. paniculata inhibit progression of ALI, we used the experimental model of lipopolysaccharide (LPS)-induced ALI in BALB/c mice to evaluate the therapeutic potential of purified ACGs. Our results showed that M. paniculata ACGs inhibited lung inflammation in animals undergoing ALI. The protective effects of ACGs were assessed by determination of cytokine levels and in situ analysis of lung inflammation. ACGs reduced the pulmonary edema and microvascular permeability, demonstrating a dose-dependent down-regulation of LPS-induced TNF-α, IL-6 and IL-1β expression in lung tissue and bronchoalveolar lavage fluid, along with reduced apoptosis. Moreover, metabolic profiling of mice serum and subsequent Ingenuity Pathway Analysis suggested that ACGs activated protective protein networks and pathways involving inflammatory regulators and apoptosisrelated factors, such as JNK, ERK1/2 and caspase-3/7, suggesting that ACGs-dependent effects were related to MAPKs and mitochondrial apoptosis pathways. These results were further supported by evaluation of protein expression, showing that ACGs blocked LPS-activated phosphorylation of p38, ERK1/2 and JNK on the MAPKs signaling, and significantly upregulated the expression of Bcl-2 whilst down-regulated Bax and cleaved caspase-3. Remarkably, ACGs inhibited the LPS-dependent TLR4 and TRPC6 upregulation observed during ALI. Our study shows for the first time that ACGs inhibit acute inflammation and apoptosis by suppressing activation of TLR4/TRPC6 signaling pathway in a murine model of ALI. Our findings provide new evidence for better understanding the anti-inflammatory effects of ACGs. In this regard, ACGs could be exploited in the development of novel therapeutics for ALI and ARDS.
Introduction
Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), are life-threatening medical conditions triggered by common pathologies such as trauma, pneumonia or sepsis. As a consequence, patients develop hypoxemic respiratory failure with high morbidity and mortality rate. ALI pathophysiology is characterized by increased permeability of the alveolar-capillary barrier and pulmonary edema as a result of macrophage activation and extensive neutrophil influx into the lungs. Infiltrating cells release cytokines that activate local pro-inflammatory networks, leading to irreversible damage of the lung epithelium and endothelial cells [1, 2] .
Lipopolysaccharide (LPS), a main component of the out membrane of gram-negative bacteria, has been identified as a potent inducer of bacterial sepsis-induced ALI [3] [4] [5] . Upon stimulation by LPS, Toll-like receptor 4 (TLR4) expressed in macrophages and endothelial cells is recruited to lipid rafts and interacts with different adaptor molecules [6, 7] , resulting in activation of downstream signaling pathways responsible for the production of pro-inflammatory cytokines and subsequent infiltration of inflammatory cells, such as neutrophils, into the lungs [8] . This uncontrolled inflammatory responses finally induce loss of normal alveolar capillary barrier function and pulmonary edema [6, 7] . In this regard, transient receptor potential channel 6 (TRPC6), a permeable non-selective cation channel, has been shown to modulate Ca 2+ entry into endothelial cells to further enhance TLR4-dependent vascular permeability and local inflammation in the lung [9, 10] . Thus, targeting the TLR4/TRPC6 axis in endothelial cells might offer novel therapeutic targets to inhibit aberrant pro-inflammatory cytokine networks in the lungs of ALI patients. However, despite our increasing understanding of the pathophysiology of ALI and ARDS [11, 12] , there is still an alarming lack of therapeutic agents to treat these conditions and the mortality rate remains high, reflecting that key events regulating pathogenesis remain elusive. Indeed, the only effective therapy against ALI consists of mechanical ventilation and there is no pharmacological approach available [13] . Thus, developing novel therapeutics for ALI is an urgent and unmet clinical need. Microcos paniculata, also known as shiral (India, Bengal), is an edible and medicinal plant, whose leaves (Microctis folium) have been used in traditional medicine for hundreds of years to relieve diseases and infections affecting the upper respiratory tract involving fever, throat irritation, cough or phlegm [14] . It has been proved that M. paniculata total flavonoids are responsible for its main therapeutic effects, which is coincided with its anti-oxidative and anti-inflammatory abilities [15] . However, little is known about the bioactivity of the apigenin C-glycosides (ACGs), the main sub-fraction found in M. paniculata total flavonoids. Recent work suggests that ACGs may act as strong anti-inflammatory compounds [16] [17] [18] [19] , although the molecular mechanism of the anti-inflammatory actions elicited by ACGs is still unknown.
In this study, we isolated and characterized M. paniculata ACGs fraction to test its anti-inflammatory potential in the LPS-induced model of ALI in Balb/c mice. Our results show that ACGs are effective at inhibiting disease progression and this was associated with a clear reduction in cellular infiltration and local inflammation as shown by histological analysis and cytokine production, such as IL-6, IL-1β and TNF-α. This provides proof of concept in the in vivo model that such compounds can be active against ALI. Furthermore, we elucidated the underlying mechanism using metabolomics analysis combined with Ingenuity Pathway Analysis, IPA. Metabolomics, which focus on a comprehensive analysis of small molecule metabolites (< 1 kDa), is highly propitious to the discovery of novel biomarkers and therapeutic targets in biomedicine [20, 21] . Combined with IPA, metabolomics is acting as one cutting-edge tool for pharmacological research [22] [23] [24] , especially for illustrating the molecular mechanism of bioactive natural products. This approach revealed that ACGs inhibited the MAPKs pathway and apoptosis pathway. Moreover, we also identified the TLR4/TRPC6 axis as a critical pathway down-regulated by ACGs to mediate protection in ALI mice.
Collectively, our data contribute to the identification of the TLR4/ MAPKs/TRPC6 axis as therapeutic target in ALI and suggest that ACGs extracted from M. paniculata could offer new molecules to therapeutically intervene these inflammatory and apoptosis pathways.
Results

Preparation, qualitative and quantitative profiling of ACGs fraction from M. paniculata
To separate the ACGs from M. paniculata in one fraction, 5 kg of M. paniculata leaves were used to isolate 7.9 g of ACGs spray-dried powder through systematic purification as described in material and methods. Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-qTOF-MS) was conducted on the isolated product to further identify the main components present in the ACGs fraction. Using the retention time, accurate molecular weight and the MS/MS fragmentation pattern with standards, eight apigenin C-glycosides were unequivocally identified, namely, vicenin-2, isoshaftoside, shaftoside, vitexin, vicenin-1, isovitexin, violanthin, isoviolanthin. (Fig. 1A-H ). These 8 molecules represented around 75% of the total content of ACGs, as shown by quantitative HPLC analysis (Fig. 1I-J ).
ACGs exert protective effects against LPS-mediated ALI in vivo
LPS-induced ALI, a well-characterized model of the human ALI [25] , was employed for testing the therapeutic potential of the isolated ACGs fraction from M. paniculata leaves. To investigate the therapeutic effects of ACGs, mice undergoing ALI were treated with ACGs (10, 20, 40 mg/ kg) and lung tissues were removed after dissection and stained with hematoxylin and eosin (H&E). As expected, LPS challenge induced distinct histological changes compared to tissue from naïve animals, including interstitial edema, alveolar wall thickening and a mass of inflammatory cells infiltrating into the lung alveolar spaces (Fig. 2) . However, ACGs treatment significantly alleviated these LPS-induced pathological changes in a dose-dependent manner (Fig. 2) . Remarkably, ALI mice treated with 40 mg/kg of ACGs displayed a lung architecture similar to naïve animals or mice treated with dexamethasone ( Fig. 2) . To assess whether ACGs had anti-inflammatory actions per se, or they were simply preventing LPS binding to TLR4 and/or its subsequent activation, the flavonoids were administered to mice that had received LPS injections 24 h before. Remarkably, ACGs still reduced lung inflammation significantly (Fig. S1) , demonstrating an intrinsic anti-inflammatory activity.
To further evaluate the protective effects of ACGs during experimental ALI, several parameters related to LPS-induced pulmonary edema and microvascular permeability were quantified, such as wet/ dry lung weight ratio, neutrophil infiltration, protein concentration in bronchoalveolar lavage fluid (BALF) and myeloperoxidase (MPO) activity in lung tissue (Fig. 3) . Treatment with ACGs (as in Fig. 1 ) essentially abrogated LPS-induced pulmonary edema and microvascular permeability, as evidenced by a significant reduction of i) lung wet/dry weight ratio (Fig. 3A) , ii) number of neutrophils and iii) protein content in BALF (Fig. 3B, C) and iv) MPO activity in tissue extracts (Fig. 3D) . Interestingly, ACGs at 40 mg/kg exerted again an anti-inflammatory 
ACGs inhibit cytokine secretion and apoptosis in LPS-induced ALI
As local expression of pro-inflammatory TNF-α, IL-6 and IL-1β has been shown to be critical for infiltration of neutrophils in the lungs during ALI progression, we also investigated whether ACGs downregulated the expression of these cytokines in vivo. Therefore, relative mRNA expression for TNF-α, IL-6 and IL-1β was evaluated in lung tissue by quantitative PCR (Fig. 4A-C) and protein levels were quantified in BALF by ELISA (Fig. 4D-F) . Results showed that ACGs inhibited the LPS-mediated up-regulation of TNF-α, IL-6 and IL-1β observed in mice undergoing ALI. Likewise, ACGs inhibited cytokine production in a dose-dependent manner, similarly to the protective effects associated to ACGs treatment in ALI mice in the histopathological and microvascular permeability analysis (Figs. 2 and 3 ). Likewise, ACGs Intranasal instillation of LPS (2 mg/kg) resulted in significantly increased wet/dry ratio and BALF neutrophils number, protein concentration as well as pulmonary MPO activity, which were markedly attenuated by ACGs treatment (n = 6 mice per group, * P < 0.05 vs con group; #P < 0.05 vs LPS treated group). treatment 24 h post LPS injection significantly reduced TNF-α and IL-6 in BALF in a dose-dependent manner (Fig. S3) . Moreover, confirming the anti-inflammatory activity of ACGs, the flavonoids strongly inhibited LPS-mediated macrophage cytokine production in vitro (Fig.  S4) .
Finally, we examined the epithelial and endothelial cell apoptosis, since it has been shown that increased apoptosis reflects the degree of tissue damage in lungs from ALI patients [26, 27] . To determine whether ACGs diminished apoptosis (and subsequent tissue damage) in ALI mice, we employed TUNEL staining to quantify the number of apoptotic cells in lung tissues (Fig. 4) . As expected, LPS-treated group showed a significant increase of apoptotic cells compared to the PBS-treated control group. However, treatment with ACGs led to significant and dose-dependent reduction in the number of apoptotic cells ( Fig. 4G-H ). These findings indicate that ACGs treatment inhibited apoptosis in the lungs of ALI mice.
Serum metabolic profiling showed distinct metabolite composition in response to ACGs
Collectively, our data provide compelling evidence for a protective effect of ACGs in the experimental LPS-dependent ALI-model. However, the molecular mechanisms triggered by ACGs were still unknown. Arachidonic acid and other polyunsaturated fatty acids are precursors of prostaglandins, leukotrienes and related compounds that have important roles as inflammatory mediators. As it is known that some flavonoids inhibit fatty acid-induced signaling by suppressing TLR4 function, we hypothesized that ACGs rewired lipid metabolism to inhibit LPS signaling and subsequent TLR4-dependent inflammation. Thus, we conducted targeted fatty acids profiling and non-targeted metabolic profiling on gas chromatography mass spectrometry (GC-MS, typical total ion chromatograms are shown in Fig. S6 ). We used principal component analysis (PCA) for multivariate analysis of the targeted fatty acids profiling data and non-targeted metabolic profiling data of control group, LPS group and ACGs (40 mg/kg) group. Data analysis identified a clear metabolic pattern associated to both LPS activation and ACGs treatment (Fig. 5) .
Likewise, data were subjected to significant difference analysis on SPSS and partial least square discriminant analysis (PLS-DA)/orthogonal partial least square discriminant analysis (OPLS-DA) on Simca-p to figure out the p-values and VIP values respectively (Fig. S7) . Significant differences between LPS group and ACGs group (40 mg/kg) were filtered by establishing p < 0.05 and VIP > 1 as the threshold. As a result, 30 metabolites, including palmitic acid (C16:0), stearic acid (C18:0), linoleic acid (C18:2n6c), arachidonic acid (C20:4n6), glyoxylic acid, 3-hydroxybutyric acid and taurine, were found to be differentially expressed (Table 1 ). This allowed us to define a metabolomics signature of ACGs biological actions.
Ingenuity Pathway Analysis of metabolomics data suggested that ACGs targets MAPKs pathway and mitochondrial apoptosis in vivo to exert their anti-inflammatory activity
To further address the mechanisms underlying ACGs-mediated protection in ALI, differentially expressed metabolite profiling data were further analyzed using Ingenuity Pathway Analysis (IPA) software , and IL-1β (C). And moreover, ACGs reduced pro-infammatory cytokines level, including TNF-α (D), IL-6 (E) and IL-1β (F). Data are expressed as mean ± SD (n = 6 mice per group, * P < 0.05 vs con group; #P < 0.05 vs LPS treated group). (G) The lung tissues were subjected to the TUNEL staining. TUNEL positive cells were indicated by arrows (magnification 100×). (H) Densitometric analysis showed that the quantity of TUNEL-positive cells was elevated in LPS group mice, and ACGs significantly reduced it (n = 6 mice per group, * P < 0.05 vs con group; #P < 0.05 vs LPS treated group).
to interpret the biological changes, altered canonical pathways and gene networks. IPA exploits relationships among differential metabolites or genes expression and it is a powerful tool for identification of significantly changed pathways in drug discovery. Therefore, we next decided to perform IPA analysis on the metabolites regulated by ACGs (Table 1) , with the goal of constructing the molecular interaction networks underlying the molecular mechanism of M. paniculata ACGs fraction on treating ALI. The highest-scoring (IPA score, 43) network targeted by ACGs involved 16 molecules (Fig. 6 ) and highlighted two major pathways (Table S1 ). Interestingly, this network involved inflammatory regulators and apoptosis-related factors directly related to modulation of the generic mitogen-activated protein kinases (MAPKs) pathway and mitochondrial apoptosis pathway, such as c-Jun N-terminal kinase (JNK), extracellular regulating kinase 1/2 (ERK 1/2) and caspase-3/7. This indicated that the anti-inflammatory mechanism of ACGs might involve down-regulation of MAPKs-dependent pathways, as well as mitochondrial apoptotic pathways.
ACGs targeted MAPKs to down-regulate inflammatory responses, whilst inhibition of apoptosis relied on modulation of mitochondrialdependent pathways
Since MAPKs are reported to be activated in LPS-induced inflammatory process, we decided to evaluate activation of the MAPKs pathway in the lung tissue of ALI mice treated with ACGs in vivo compared to control mice. Confirming the results generated by IPA analysis, ACGs efficiently blocked LPS-dependent phosphorylation of p38, ERK1/2 and JNK (Fig. 7A-D) , as evaluated by western blotting. Similarly, we also measured expression of described mitochondrial apoptosis-related factors, both anti-apoptotic, Bcl-2, and pro-apoptotic, Bax and caspase-3. Whilst LPS down-regulated the expression of Bcl-2, ACGs treatment restored the expression of Bcl-2 to homeostatic levels (Fig. 7E, F) , suggesting that ACGs maintained Bcl-2 activity to inhibit apoptosis. Moreover, compared with the control group, LPS induced a marked increase in the expression of anti-apoptotic Bax and cleaved caspase-3, which were attenuated by ACGs treatment (Fig. 7E, G,  H) . On the basis of these results, we concluded that ACGs suppressed apoptosis in LPS-induced ALI by targeting apoptotic through mitochondrial pathways.
TLR4 activation of TRPC6 signaling pathway is involved in LPSinduced ALI
Given the strong down-regulation of MAPKs activation by ACGs (which was even more powerful than dexamethasone when used at 40 mg/kg), we hypothesized that additional mechanisms may be triggered by ACGs to deactivate LPS-mediated TLR4 signaling. Regarding this, it has been described that Ca 2+ entry upon activation of TRPC channels accounts for the increased permeability and inflammation of lung. Therefore, we hypothesized that TLR4 interferes with TRPC channels function in mediating lung vascular leakage and inflammation. To test this hypothesis, we examined the expression of TLR4 and TRPC6 in mice undergoing ALI in the presence or absence of increasing concentrations of ACGs as before. Interestingly, we observed that ACGs down-regulated expression of both TLR4 and TRPC6 induced by LPS in vivo (Fig. 8A-C) .
Discussion
In the present study, we have set up a simple process to isolate ACGs from M. paniculata leaves and we found that ACGs attenuated LPS-induced ALI through modulation of TLR4/TRPC6 pathway, reducing the release of pro-inflammatory cytokines, and regulating the expression of apoptosis-related factors. Thus, our results show that ACGs contain valuable therapeutic potential for human ALI. We chose the LPS-induced ALI to test the therapeutic potential of ACGs because it is a well-accepted model of human ALI, since it recapitulates important aspects of the human disease, such as the disrupted alveolar epithelial and endothelial barrier function, cell infiltration, and local inflammatory responses [25, 28] . Given the success of M. paniculata in traditional medicine to treat pulmonary inflammation, it was important to isolate and characterize its bioactive molecules. Even though previous studies in the last 20 years suggested that some anti-inflammatory substances (glucocorticoids, inhaled nitric oxide or Ketoconazole) [29, 30] exert anti-inflammatory responses during LPS-induced ALI, none of these drugs has been translated to therapy, and are limited to assist in disease management. Thus, there is still an urgent need for pharmacological options, that could be found in M. paniculata ACGs. We demonstrated that ACGs protect against LPSinduced ALI by exerting a number of synergistic actions in vivo, including inhibition of interstitial edema, maintenance of alveolar-capillary barrier and reduction of cytokine production and infiltration of activated neutrophils. Neutrophils are key disease mediators in the lungs, since they induce tissue damage by releasing pro-inflammatory cytokines and generating reactive oxygen species (ROS) [31, 32] . Accordingly, depletion of neutrophils inhibited progression of experimental ALI and neutrophils in the BALF of patients with ARDS is associated with a poor disease outcome [33] . Interestingly, we observed that ACGs-mediated protection during ALI was associated with, not only a reduction of neutrophil infiltration in the lungs, but also a reduced cell activation. This is the first observation of an anti-inflammatory molecule inhibiting neutrophil-dependent inflammatory responses in ALI. Supporting this, ACGs treatment down regulated expression of pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1ß, both in the lung tissue and BALF. Therefore, our results provide evidence for a novel anti-inflammatory role of ACGs at multiple levels, including neutrophil recruitment and activation, pro-inflammatory cytokine networks and epithelial barrier permeability. ACGs also reduced LPS-mediated inflammation 24 h after the challenge, demonstrating that ACGs might have anti-inflammatory activity directly (via a mechanism that might be independent of competing for TLR4 binding) such as inhibition of caspases and Bcl-2 family members, well-known regulators of apoptosis, or the observed regulation of the three apoptosis-related molecules targeted by ACGs in vivo: Bcl-2, caspase-3 and Bax. In line with this, many studies have shown that increased apoptosis of epithelial and endothelial cells significantly contribute to compromise the alveolar-capillary barrier integrity [34] . Nevertheless, direct and indirect mechanisms to suppress TLR4 activation are not mutually exclusive and both might be acting synergistically upon ACGs treatment.
To further explore the mechanisms underlying the ACGs actions, we evaluated fatty acid metabolism, as hydrophobic fatty acids are precursors of prostaglandins and leukotrienes, crucial inflammatory molecules that provide a link between cellular metabolism and inflammation, which could explain the diverse anti-inflammatory mechanisms triggered by ACGs in vivo. In fact, some flavonoids have been shown to inhibit fatty acid-induced signaling by uncoupling TLR4-dependent pathways. Although it is still not completely understood how ACGs-dependent modulation of metabolite networks can regulate inflammatory responses, it is becoming increasingly clear that metabolism and inflammatory mechanisms are intimately connected. For example, the most elevated metabolites in ACGs-treated mice are β-hydroxybutyrate, L-asparagine and taurine, that have been reported to inhibit NLRP3 inflammasome [35] , AMP-activated protein kinase signaling pathways [36] and IL-1β and IL-6 expression [37, 38] respectively, suggesting that ACGs rewire cellular metabolism towards a less inflammatory phenotype to control progression of ALI. (cum) = 0.6447]. "con", control group, which was in red triangles; "LPS", LPS group, which was presented by blue triangles; "ACGs 40", apigenin C-glycosides group (40 mg/kg), which was showed in green triangles.
Using the bioinformatic IPA integrated with the current understanding of signaling pathways, analysis of the full list of modulated metabolites allowed us to generate a molecular network to reveal that ACGs targeted MAPKs pathway and mitochondrial apoptosis pathways, both major regulators of inflammation. Indeed, some of the ACGs described here, such as vitexin and isovitexin, have been defined as inhibitors of MAPKs pathways in other inflammatory conditions [39, 40] . Confirming this, our data show that ACGs have a strong potential to specifically inhibit MAPK-dependent inflammation, as they reduced ERK1/2, JNK and p38 activation upon LPS challenge. However, MAPKs are known to modulate many inflammatory mediators, suggesting that ACGs may affect production of other mediators not identified in this study. Similarly, it is known that LPS-dependent activation of TLR4 is involved in neutrophil activation and recruitment to the lungs during ALI, and TLR4 activation in endothelial and epithelial cells also contributes to the loss of lung vascular barrier function [10, 32, 33] . In relation with this, elevated levels of intracellular Ca 2+ seem to precede endothelial and epithelial cells barrier dysfunction [41] , but it is unknown whether Ca 2+ signaling pathways intersect with TLR4 signaling in ALI, or whether these contribute to LPS-induced inflammation and apoptosis. We observed that ACGs inhibited the expression of TLR4, which could explain some of the anti-inflammatory actions described before, like the reduced IL-1β, IL-6 and TNF-α expression, or the inhibition of the MAPKs pathway, but rather interestingly, ACGs also down-regulated expression of TRPC6, a member of the Ca 2+ permeable Transient Receptor Potential (TRP) channels [42, 43] , perhaps providing in ALI a synergistic mechanism between intracellular Ca 2+ influx and TLR4/mediated inflammation as proposed before [44] . ACGs might inhibit the increase of intracellular Ca 2+ upon TLR4/TRPC6 activation and associated MAPKs pro-inflammatory signaling, which results in increased pro-inflammatory cytokine production and apoptosis of endothelial cells and subsequent loss of endothelial barrier integrity. Thus, although full understanding of the mechanisms underpinning ACGs-mediated protection in ALI requires further work, we propose that ACGs target the TLR4/TRPC6 inflammatory system, activated upon LPS interaction during ALI initiation. By targeting this inflammatory cascades, ACGs may protect against ALI in a novel and highly efficient way (Fig. 9) . Therefore, this study indicates that there is great medicinal potential to be found amongst the ACGs isolated from Microcos paniculata. Furthermore, M. paniculata has been used for centuries in China as medicinal herb, and it is currently employed in commercialized herbal tea in China, suggesting that anti-inflammatory compounds based on M. paniculata ACGs might not have significant drawbacks or immunosuppressive side-effects often associated to other anti-inflammatory therapies. Thus, the structures elucidated here might provide a novel platform for a rational development of novel and safer antiinflammatory drugs to treat human ALI, but perhaps to other inflammatory conditions, where TLR4-dependent signaling plays a crucial role in disease initiation and progression as well.
Materials and methods
Preparation of M. paniculata ACGs fraction
Dried M. paniculata leaves (5 kg) were extracted with water (80 L, 2 times) at 95-100°C for 2 h. The water filtrate was concentrated and passed through a D101 macro-porous resin column (i.d. 20 cm × 150 cm, Xi'an Sunresin New Materials Co. Ltd., China) and then eluted with 10%, 70% and 95% EtOH. The 70% EtOH eluate was further purified with Sephadex LH-20 column (GE healthcare, 7 cm × 60 cm) with MeOH-H 2 O (80:20) , and the purified flavonoids were further separated by preparative HPLC with C18 column (20 mm × 250 mm, 10 µm, Hanbang technology Co., Ltd., China) and the elution rich of ACGs was then collected, concentrated and spray-dried.
The specific compounds of ACGs were further isolated and purified using semi-preparative high performance liquid chromatography, and then characterized using 1 H NMR, 13 C NMR and HRMS. 
Ultra performance liquid chromatography time of flight mass spectrometry analysis
Identification of compounds from M. paniculata ACGs fraction was carried out using a 1290 UHPLC-6545-QTOF-MS (Agilent Corporation, MA, USA) [45] . The mobile phase was a mixture of methanol (A) and water containing 0.05% formic acid (B) using a liner gradient of 0-7.6 min，85% → 60% (B)；7.6-10 min, 60% → 60% (B)；10-12 min, 60% → 30% (B)；12-15 min, 30% → 20% (B)；15-16 min, 20% → 0% (B)；16-20 min, 0% → 0% (B). The flow rate was set as 0.2 mL/min and injection amount was 2 µL. The column temperature was set to 35 ℃. Mass spectrometry was programmed in a negative ion mode with a scan scale of 50-1000 m/z. The source temperature was set to 150 ℃ and a source voltage was 3.5 kV. The wavelength for ultraviolet (UV) detector was 276 nm.
High performance liquid chromatography analysis
Quantitative profiling of M. paniculata ACGs fraction was performed on HPLC (LC-20AT, Shimadzu, Japan) with a Kromasil C18 column (250 mm × 4.6 mm, 5 µm) [46] . The mobile phase was methanol (A) and water containing 0.2% phosphoric acid (B) with a flow rate of 1 mL/min, using a gradient of 0-12 min, 82% → 70% (B); 12-45 min, 70% → 55% (B); 45-60 min, 55% → 20% (B). The injection volume was 10 µL and the wavelength for UV detector was 276 nm.
Animals and LPS-induced ALI
Male Balb/C mice were obtained from Guangzhou University of Chinese Medicine (Guangzhou, China). Animal study protocols were reviewed and approved by the Ethics Committee of Guangzhou Medical University. All animals studies were conducted in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines for reporting experiments involving animals [47, 48] . Mice, 8-10 weeks, were randomly divided into the following six groups (n = 12): control, LPS, LPS + ACGs (10 mg/kg, 20 mg/kg and 40 mg/kg), LPS + Dexamethasone (Dex, 10 mg/kg). ALI was induced by intratracheal instillation of LPS (Sigma, E.coli 055:B5, 2 mg/kg, dissolved in PBS) according to previous study with minor modifications [49] . Mice treated with PBS in a similar way was used as a non-inflammatory control. ACGs was given for three times by intragastric administration (an equal volume of 0.5% CMC-Na (carboxymethycellulose sodium) was given to control group) and Dex was administered three times by intraperitoneal injection in LPS-treated group mice at days − 1, 0 and + 1, being day 0 the day of the LPS administration. For day 0, both ACGs and Dex were injected 2 h prior to the LPS challenge. 48 h after LPS administration, lung tissues, serum and BALF were harvested. All animals were maintained under standard laboratory conditions, housed with 12 h light/dark cycles at controlled 22-24°C and 60-65% humidity. A total of 90 mice were used in this study, and the mice were acclimatized to the environment for 7 days before experiments.
Histopathologic evaluation of the lung tissue
Lung tissues were washed three times with cold PBS and fixed in 4% paraformaldehyde followed by paraffin embedding, then cut into 4 µm sections, and stained with hematoxylin and eosin (H&E). Pathological changes in the lung tissues were evaluated by light microscope.
Lung wet/dry ratio
The middle lobe of right lungs were harvested and weighed. Lung tissue was heated in a thermostatic oven at 60 ℃ for 48 h and then weighed to determine the baseline dry weight of lung. Densitometric analysis showed that LPS decreased the expression of Bcl-2 and increased the expression of Bax and cleaved caspase-3, which was reversed by ACGs treatment (n = 5, *P < 0.05 vs con group; #P < 0.05 vs LPS treated group).
Bronchoalveolar lavage fluid (BALF) analysis
BALF was collected by intratracheal administration of 1 mL PBS into the lung and pumped back and forth gently for 3 times. The BALF was centrifuged (1500 rpm, 10 min, 4 ℃) to pellet the cells. The total cells were resuspended in 100 µL PBS, then neutrophils were identified and numbers quantified by Wright-Giemsa staining. Protein concentration in the supernatant was measured by BCA protein assay kit. Levels of TNF-α, IL-1β and IL-6 in the supernatant were quantified using ELISA kit from Neobioscience (Shenzhen, China) according to the manufacturer's instructions.
Assessment of MPO activity
MPO activity in the lung tissues was assessed with MPO assay kit according to the manufacturer's instructions Neobioscience (Shenzhen, China). Changes in OD value were measured at 460 nm to calculate MPO activity.
TUNEL Staining
Lung tissues were fixed in 4% paraformaldehyde prior to paraffin embedding, and then cut into 4 µm sections. Then, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining was used to evaluate apoptosis rate as established method [50] . Fluorescence staining was conducted using in situ Cell Death Detection Kit from Roche according to the manufacturer's instructions. The apoptotic cells were observed under light microscope and the results were expressed as the average number of TUNEL-positive staining cells per 100× magnification field.
Quantitative RT-PCR
Total RNA was extracted from mice lung tissues with Trizol reagent (Invitrogen, Carlsbad, CA) as described previously [51] . Mouse-specific primers for Tumor Necrosis Factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and β-actin were purchased from Invitrogen (Carlsbad, CA). Total RNA was reversely transcribed to first strand cDNA using one-step RT kit (Takara Biotechnology, Dalian, CN) for one microgram sample. mRNA expression levels were determined using SYBR-Green Quantitative PCR Kit (Takara Biotechnology, Dalian, CN) on an ABI StepOne™ real-time PCR system (Themo Fisher Scientific Inc., CA). The 2 (−ΔΔCT) method was used to determine the relative expression of mRNA. The amount of each gene was normalized to the amount of β-actin.
Western blotting
Western blotting was conducted as previous described [52] , protein concentration was determined by BCA method. Briefly, protein content was separated on SDS-PAGE and transferred to PVDF membrane. The membrane was then blocked with 5% non-fat milk at room temperature for 2 h, following incubation with the primary antibodies against Bcl-2, Bax, cleaved caspase-3, ERK1/2, JNK, p38, TLR4 and TRPC6 (all from cell signaling, Boston, MA) at 4 ℃ overnight. Subsequently, the membrane was incubated with appropriated HRP-conjugated secondary antibody (cell signaling, Boston, MA) for 1 h. GAPDH (Boster Biological Technology, Wuhan, CN) was used as loading control. Target bands were developed using a chemiluminescence system and then visualized by exposure to Kodak X-ray film. Image J software was used for band densitometry. Targeted fatty acids profiling of mice serum was carried on 7890B-5977B GC-MS (Agilent, MA, USA) with a DB-23 column (60 m × 0.25 mm × 0.15 µm, Agilent, MA, USA). The temperature programming was set to 50 ℃, 0.5 min → 50-140 ℃ (20 ℃/min), 5 min → 140-240 ℃ (4 ℃/min), 5 min. The auxiliary temperature was 240 ℃ and the injector temperature was 250 ℃ with 1.0 µL injection volume (10:1 split ratio). The helium carrier gas flow rate was set at 1 mL/min. MS detection was used selective ion scanning m/z 40-500 amu. The EI source temperature was 230 ℃. The MS quadrupole temperature were maintained at 150 ℃.
4.13. Non-targeted metabolic profiling of mice serum 50 µL of mice's plasma was mixed with 10 µL of nonadecanoic acid methanol solution (1 mg/mL, w/v) and 250 µL of H 2 O-MeOH-CHCl 3 solution (2:5:2, v/v/v), then stayed at 4 ℃ for 20 min. The mixture was next centrifuged at 14,000 rpm for 15 min at room temperature. 200 µL of supernatant was taken and dried in nitrogen, which was followed by mixed with 80 µL of methoxyamine pyridine solution (15 mg/mL, w/v) and incubated at 37 ℃ for 90 min. Finally, 80 µL of bis-(trimethylsilyl) trifluoroacetamide (BSTFA) with 1% chlorotrimethyl-silane (TMCS) was added and incubated at 70 ℃ for 1 h. Nonadecanoic acid was used as internal standard substance.
The metabolic profiling was performed on 7890B-5977B GC-MS with a HP-5MS column (60 m × 0.25 mm × 0.25 µm, Agilent, MA, USA). The temperature was programmed to 60 ℃, 1 min → 60-100 ℃ (8 ℃/min), 5 min → 100-170 ℃ (15 ℃/min), 5 min → 170-210 ℃ (10 ℃/min), 5 min → 210-350 ℃ (10 ℃/min), 5 min. The auxiliary temperature was 240 ℃. The injector temperature was 250 ℃ and injection volume was 1.0 µL. The helium carrier gas flow rate was set at 1 mL/min. MS detection was used selective ion scanning m/z 50-600 amu. The EI source was 230 ℃. The MS quadrupole were maintained at 150 ℃.
Data processing of GC-MS metabolic analysis
The total ion chromatogram (TIC) of GC-MS analysis were processed with Masshunter workstation B.07.00 (Agilent Technologies Co., Ltd, USA) for search and identification of compounds in NIST14.L database. The peaks of metabolites were detected, aligned and quantified by being imported to Quantitative Analysis (MS) (Agilent Technologies Co., Ltd, USA), which then were normalized by reference substances or internal standard.
Statistical analysis
All data are expressed as means ± standard deviation (SD). A Student's t-test was carried out and P < 0.05 was considered statistically significant. The principal component analysis (PCA) and partial least-squares discriminant analysis (PLS-DA) were performed on Simcap 11.0 (Umetrics, Umeå, Sweden). Graphpad Prism 6.0 software (GraphPad, CA, USA) was used for graphics.
Molecular network construction using IPA
Construction of the metabolic interaction network among differential metabolites were performed on Ingenuity Pathways Analysis (IPA, QIAGEN, Germany). IPA is a web-based software application (http://www.ingenuity.com) that identifies biological pathways and functions relevant to biomolecules of interest. The list of modulated metabolites and their KEGG identification upon LPS or ACGs treatment were uploaded to IPA with the corresponding fold change to display molecular interaction networks as described before [22] [23] [24] . Interactions among metabolites were generated based on the Ingenuity Pathway Knowledge Data Base. For correlations, a network score was based on the hypergeometric distribution and was calculated with the right-tailed Fisher's Exact Test. High scores indicate more relevant interactions for the network construction.
